Loading
Alzheimers Disease · Observational Study
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned post-authorization observational registry study of LEQEMBI safety and disease progression in routine clinical practice, not yet recruiting and with no results reported. It will characterize the incidence and severity of known adverse events (including ARIA and intracerebral hemorrhage) stratified by APOE4 genotype, antithrombotic use, and baseline MRI findings, and will document previously unknown safety signals and disease progression patterns.
Observational. Alzheimers Disease. Intervention: Participants Treated With LEQEMBI. n = 400. 11 sites: Canada.
This is a planned post-authorization observational registry study of LEQEMBI safety and disease progression in routine clinical practice, not yet recruiting and with no results reported. It will characterize the incidence and severity of known adverse events (including ARIA and intracerebral hemorrhage) stratified by APOE4 genotype, antithrombotic use, and baseline MRI findings, and will document previously unknown safety signals and disease progression patterns.
No efficacy outcomes planned; primary focus is on safety and adverse events.
The source did not state who this applies to in practice.
This is a planned observational registry study with no results yet reported; it will characterize safety and disease progression in routine clinical practice but cannot yet inform clinical decisions.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07762092). This is a study registration, not published results. Lead sponsor: Eisai Limited. Recruitment status: NOT_YET_RECRUITING. Study type: OBSERVATIONAL. Enrollment: 400 participants (ESTIMATED). Conditions: Alzheimers Disease. Interventions: OTHER: No Intervention. Primary outcome measures: Incidence and Severity of Known AEs , Up to 3 years. Brief summary: To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm in diameter in participants treated with LEQEMBI during routine clinical practice, summarizing the data overall and by apolipoprotein E4 variant (APOE4) genotype, concomitant antithrombotic therapy, and baseline magnetic resonance imaging (MRI) findings (comorbid cerebral amyloid angiopathy \[CAA\]). The secondary purpose of this study is, To describe progression to the next stage of Alzheimer's Disease (AD), stratified by ARIA and intracerebral hemorrhage greater than 1 cm. To describe previously unknown adverse events related to the long-term safety of LEQEMBI in routine clinical practice, which were not identified in clinical development, as assessed by serious suspected adverse reactions, adverse reactions leading to discontinuation of LEQEMBI treatment, and deaths that occur within 30 days of discontinuation of LEQEMBI treatment (regardless of causality). To describe drug utilization of LEQEMBI and to assess the effectiveness of risk minimization measures in routine clinical practice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.